Asimadoline

Summary

Asimadoline (CHEMBL1190199) is a phase-3 clinical-stage small molecule targeting OPRK1; indicated across 2 conditions including irritable bowel syndrome and ileus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Targets: 1 (OPRK1)
• Indications: 2 conditions
• Clinical trials: 7
• Chemistry: 414.5 Da · C27H30N2O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1190199
Name	Asimadoline
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	179340
Molecular formula	C27H30N2O2
Molecular weight	414.5
InChIKey	JHLHNYVMZCADTC-LOSJGSFVSA-N

SMILES: CN([C@H](CN1CC[C@@H](C1)O)C2=CC=CC=C2)C(=O)C(C3=CC=CC=C3)C4=CC=CC=C4

IUPAC name: N-[(1S)-2-[(3S)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-N-methyl-2,2-diphenylacetamide

Also known as: Asimadolina, Asimadoline, EMD-61753, ASIMADOLINE

Parent form; salt/anhydrous children: CHEMBL540342

Patent coverage: 392 distinct patent families (1,816 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
OPRK1	κ receptor	Agonist	9	0%	P41145

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Mu-type opioid receptor, Delta-type opioid receptor, Kappa-type opioid receptor.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
OPRK1	9.3	EC50	0.5	nM	CHEMBL_ACT_15145620
OPRK1	8.25	Ki	5.6	nM	CHEMBL_ACT_25611623
OPRD1	5.1	EC50	8000	nM	CHEMBL_ACT_15145577

Target pathways

Aggregated over 1 target gene(s): OPRK1.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Peptide ligand-binding receptors	1	OPRK1
G alpha (i) signalling events	1	OPRK1
MECP2 regulates neuronal receptors and channels	1	OPRK1

Dominant GO biological processes

GO term	Targets
immune response	1
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	1
phospholipase C-activating G protein-coupled receptor signaling pathway	1
neuropeptide signaling pathway	1
chemical synaptic transmission	1
sensory perception	1
locomotory behavior	1
sensory perception of pain	1
adenylate cyclase-inhibiting opioid receptor signaling pathway	1
response to insulin	1
positive regulation of dopamine secretion	1
negative regulation of luteinizing hormone secretion	1
response to nicotine	1
G protein-coupled opioid receptor signaling pathway	1
maternal behavior	1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
irritable bowel syndrome	3	MONDO:0005052	EFO:0000555
ileus	2	MONDO:0004567	MONDO:0004567

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	5
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01100684	PHASE3	COMPLETED	Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
NCT07042516	PHASE2	RECRUITING	Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).
NCT00443040	PHASE2	TERMINATED	Asimadoline for the Treatment of Post-Operative Ileus
NCT00454688	PHASE2	COMPLETED	Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome
NCT00955994	PHASE2	COMPLETED	Effect of Asimadoline, a Member of a New Medication Class, on Acute Attacks of Pain in Irritable Bowel Syndrome
NCT02475447	PHASE2	COMPLETED	Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis
NCT01380561	PHASE1	COMPLETED	A Metabolite Identification, Mass Balance, and PK Study of [14C]-Asimadoline to Healthy Adult Male Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

347 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
ACLIDINIUM BROMIDE	ChEMBL + PubChem	Phase 4 (approved)	OPRK1
ALOGLIPTIN	ChEMBL + PubChem	Phase 4 (approved)	OPRK1
PROPOXYPHENE	ChEMBL + PubChem	Phase 4 (approved)	OPRK1
ACRIVASTINE	ChEMBL	Phase 4 (approved)	OPRK1
ALMITRINE	ChEMBL	Phase 4 (approved)	OPRK1
ALPIDEM	ChEMBL	Phase 4 (approved)	OPRK1
ALPRAZOLAM	ChEMBL	Phase 4 (approved)	OPRK1
ALVIMOPAN	ChEMBL	Phase 4 (approved)	OPRK1
AMBENONIUM	ChEMBL	Phase 4 (approved)	OPRK1
AMIODARONE	ChEMBL	Phase 4 (approved)	OPRK1
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	OPRK1
AMLODIPINE	ChEMBL	Phase 4 (approved)	OPRK1
AMOXAPINE	ChEMBL	Phase 4 (approved)	OPRK1
AMSACRINE	ChEMBL	Phase 4 (approved)	OPRK1
APOMORPHINE	ChEMBL	Phase 4 (approved)	OPRK1
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	OPRK1
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	OPRK1
ATAZANAVIR	ChEMBL	Phase 4 (approved)	OPRK1
ATOMOXETINE	ChEMBL	Phase 4 (approved)	OPRK1
ATRACURIUM	ChEMBL	Phase 4 (approved)	OPRK1
AZATADINE	ChEMBL	Phase 4 (approved)	OPRK1
BACAMPICILLIN	ChEMBL	Phase 4 (approved)	OPRK1
BECLOBRATE	ChEMBL	Phase 4 (approved)	OPRK1
BENPERIDOL	ChEMBL	Phase 4 (approved)	OPRK1
BENZNIDAZOLE	ChEMBL	Phase 4 (approved)	OPRK1
BENZPHETAMINE	ChEMBL	Phase 4 (approved)	OPRK1
BENZTROPINE	ChEMBL	Phase 4 (approved)	OPRK1
BEPRIDIL	ChEMBL	Phase 4 (approved)	OPRK1
BIFONAZOLE	ChEMBL	Phase 4 (approved)	OPRK1
BISACODYL	ChEMBL	Phase 4 (approved)	OPRK1
BOSUTINIB	ChEMBL	Phase 4 (approved)	OPRK1
BROMOCRIPTINE	ChEMBL	Phase 4 (approved)	OPRK1
BROMPERIDOL	ChEMBL	Phase 4 (approved)	OPRK1
BUCLIZINE	ChEMBL	Phase 4 (approved)	OPRK1
BUFLOMEDIL	ChEMBL	Phase 4 (approved)	OPRK1
BUPRENORPHINE	ChEMBL	Phase 4 (approved)	OPRK1
BUPROPION	ChEMBL	Phase 4 (approved)	OPRK1
BUTOCONAZOLE	ChEMBL	Phase 4 (approved)	OPRK1
BUTORPHANOL	ChEMBL	Phase 4 (approved)	OPRK1
CALCITRIOL	ChEMBL	Phase 4 (approved)	OPRK1
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	OPRK1
CANNABIDIOL	ChEMBL	Phase 4 (approved)	OPRK1
CANRENONE	ChEMBL	Phase 4 (approved)	OPRK1
CARTEOLOL	ChEMBL	Phase 4 (approved)	OPRK1
CARVEDILOL	ChEMBL	Phase 4 (approved)	OPRK1
CHLOPHEDIANOL	ChEMBL	Phase 4 (approved)	OPRK1
CHLORDIAZEPOXIDE	ChEMBL	Phase 4 (approved)	OPRK1
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	OPRK1
CHLOROXINE	ChEMBL	Phase 4 (approved)	OPRK1
CHLORPROMAZINE	ChEMBL	Phase 4 (approved)	OPRK1
CICLESONIDE	ChEMBL	Phase 4 (approved)	OPRK1
CILOSTAZOL	ChEMBL	Phase 4 (approved)	OPRK1
CINACALCET	ChEMBL	Phase 4 (approved)	OPRK1
CINNARIZINE	ChEMBL	Phase 4 (approved)	OPRK1
CISAPRIDE	ChEMBL	Phase 4 (approved)	OPRK1
CLEMASTINE	ChEMBL	Phase 4 (approved)	OPRK1
CLIOQUINOL	ChEMBL	Phase 4 (approved)	OPRK1
CLOBAZAM	ChEMBL	Phase 4 (approved)	OPRK1
CLOFAZIMINE	ChEMBL	Phase 4 (approved)	OPRK1
CLOMIPRAMINE	ChEMBL	Phase 4 (approved)	OPRK1